{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-029667","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2024-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.747387+00:00","generated_at":"2026-06-04T23:01:45.690904+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Corbus Pharma reports Q4 net loss $8.0M; cash $127M after $116M raise; CRB-701 shows 43% ORR","bullets":["Net loss Q4 $8.0M ($1.81/diluted) vs $10.9M ($2.61) YoY; full year loss $44.6M ($10.31).","Cash, equivalents & investments $127M as of Feb 2, 2024 after $116M capital raise; runway 3+ years through Q1 2027.","CRB-701 (Nectin-4 ADC) Ph1 data: 43% ORR, 71% DCR at >=2.7 mg/kg; no DLTs, neuropathy, or skin rash. US Ph1 patient dosing starts March 2024.","FDA cleared IND for CRB-601 (TGFβ blocker); Ph1 start summer 2024. CRB-913 (CB1 inverse agonist) IND filing on track for Q4 2024.","Appointed Dr. Dominic Smethurst as CMO, previously CMO of Bicycle Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-029667","json":"https://secwatch.observer/filing/0000950170-24-029667.json","markdown":"https://secwatch.observer/filing/0000950170-24-029667.md","text":"https://secwatch.observer/filing/0000950170-24-029667.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024029667/0000950170-24-029667-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024029667/crbp-20240312.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:01:45.690904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2f0b7e61017655f7c234050fc2b38856489c1013","claim":"Corbus Pharmaceuticals Holdings, Inc. reported the fourth quarter of 2023 and year-ended 2023 results: net income the Company reported a net loss of approximately $8.0 million, or a net loss per diluted share of $1.81, for the three m, EPS a net loss per diluted share of $1.81, for the three months ended December 31, 2023... a net loss per diluted share of $.","evidence_excerpt":"The Company reported a net loss of approximately $8.0 million, or a net loss per diluted share of $1.81, for the three months ended December 31, 2023, compared to a net loss of approximately $10.9 million, or a net loss per diluted share of $2.61, for the same period in 2022. For the year ended December 31, 2023, the Company reported a net loss of approximately $44.6 million, or a net loss per diluted share of $10.31, compared to a net loss of approximately $42.3 million, or a net loss per diluted share of $10.15 for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024029667/0000950170-24-029667-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2023 and year-ended 2023"},{"label":"Net income","value":"the Company reported a net loss of approximately $8.0 million, or a net loss per diluted share of $1.81, for the three m"},{"label":"EPS","value":"a net loss per diluted share of $1.81, for the three months ended December 31, 2023... a net loss per diluted share of $"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}